Meeting
2023 ASCO Annual Meeting
A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.
Authors
Jordi Rodon Ahnert
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Jordi Rodon Ahnert , David R. Spigel , Jill Kremer , Leah Jin , Karim Adnane Benhadji , Maciej Gil , Benjamin Besse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04982926
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3165)
DOI
10.1200/JCO.2023.41.16_suppl.TPS3165
Abstract #
TPS3165
Poster Bd #
357a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
First Author: John Heymach
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations.
First Author: Anthony W. Tolcher
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok
Poster
2022 ASCO Annual Meeting
A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors.
First Author: Kevin Joseph Harrington